Compare PAM & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAM | TLX |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | Argentina | Australia |
| Employees | 1847 | 1184 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.6B |
| IPO Year | N/A | N/A |
| Metric | PAM | TLX |
|---|---|---|
| Price | $85.47 | $9.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $94.50 | $21.13 |
| AVG Volume (30 Days) | ★ 220.2K | 190.6K |
| Earning Date | 05-06-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $204,770.38 | N/A |
| Revenue Next Year | $16.65 | N/A |
| P/E Ratio | ★ $13.79 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.95 | $6.28 |
| 52 Week High | $94.50 | $17.25 |
| Indicator | PAM | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 54.54 |
| Support Level | $78.87 | $9.46 |
| Resistance Level | $89.81 | $10.33 |
| Average True Range (ATR) | 3.29 | 0.27 |
| MACD | 0.25 | 0.07 |
| Stochastic Oscillator | 52.54 | 86.21 |
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.